Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan;197(1):e63849.
doi: 10.1002/ajmg.a.63849. Epub 2024 Aug 21.

Recurrent carotid paragangliomas in a syndromic patient with a heterozygous missense variant in DNA Methyltransferase 3 Alpha

Affiliations
Case Reports

Recurrent carotid paragangliomas in a syndromic patient with a heterozygous missense variant in DNA Methyltransferase 3 Alpha

Ryan J German et al. Am J Med Genet A. 2025 Jan.

Abstract

We report a 40-year-old African American female with a novel variant in exon 8 of DNA methyltransferase 3 alpha (DNMT3A), (NM_022552.4: c.905G>C, p.G302A) who presented with a history of recurrent carotid paragangliomas, mediastinal mass, intellectual disability, dysarthria, cholelithiasis, diabetes mellitus, hypertension, and dysmorphic features. We interpret this novel variant as likely pathogenic and causative for the patient's syndromic features of Heyn-Sproul-Jackson syndrome. Heyn-Sproul-Jackson syndrome is a condition caused by gain-of-function genetic changes in DNMT3A. Paragangliomas have also been observed in non-syndromic patients with genetic alterations in DNMT3A. We describe a patient with clinical features of Heyn-Sproul-Jackson syndrome such as intellectual disability, dysarthria, brachydactyly, and lack of brain MRI findings to add evidence to associate paragangliomas with DNMT3A and draw particular attention to the potential involvement of the proline-tryptophan-tryptophan-proline domain of DNMT3A.

Keywords: DNMT3A; exome sequencing; hypermethylation; paraganglioma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

B.S. is a funder and shareholder of EpiSign Inc., involved in commercial uses of EpiSign™ technologies.

References

    1. Bjornsson HT (2015). The Mendelian disorders of the epigenetic machinery. Genome Research, 25(10), 1473–1481. 10.1101/gr.190629.115 - DOI - PMC - PubMed
    1. Chen T, Ueda Y, Xie S, & Li E (2002). A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation. The Journal of Biological Chemistry, 277(41), 38746–38754. 10.1074/jbc.M205312200 - DOI - PubMed
    1. Futagawa H, Ito S, Kosaki K, Yoshihashi H 2023. Long-term clinical course of Heyn-Sproul-Jackson syndrome. Congenit Anom (Kyoto) 63: 174–175. 10.1111/cga.12532 - DOI - PubMed
    1. Heyn P, Logan CV, Fluteau A, Challis RC, Auchynnikava T, Martin C-A, Marsh JA, Taglini F, Kilanowski F, Parry DA, Cormier-Daire V, Fong C-T, Gibson K, Hwa V, Ibáñez L, Robertson SP, Sebastiani G, Rappsilber J, Allshire RC, … Jackson AP (2019). Gain-of-function DNMT3A mutations cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions. Nature Genetics, 51(1), 96–105. 10.1038/s41588-018-0274-x - DOI - PMC - PubMed
    1. Kim GH, Kim J, Lee J, Jang D-H 2023. A novel pathogenic variant of DNMT3A associated with craniosynostosis: a case report of Heyn-Sproul-Jackson syndrome. Front. Pediatr. 11: 1165638. 10.3389/fped.2023.1165638, - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources